Furthermore, HOCl and another MPO oxidant—HOSCN—modify low density lipoprotein (LDL), thereby interfering with endothelial vasorelaxation and inducing endothelial dysfunction [35]. This evidence concerns the gene MPO and endothelial dysfunction.